Create
Log in
Sign up
Golden has been acquired by ComplyAdvantage.
Read about it here ⟶
A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE)
Overview
Structured Data
Issues
Contributors
Activity
Access by API
Access by API
Is a
Clinical study
0
Allocation Type
Randomized
0
Trial Collaborator
Eli Lilly
0
Participating Facility
King George Hospital
0
University of Calgary
0
University of Washington Medical Center
0
National Taiwan University Hospital
0
Tel Aviv Sourasky Medical Center
0
Sheba Medical Center
0
Oklahoma Medical Research Foundation
0
Washington University School of Medicine
0
Seoul National University Bundang Hospital
0
University of Colorado School of Medicine
0
•••
Health Conditions in Trial
Systemic lupus erythematosus
0
Intervention Model
Parallel Assignment
0
Intervention Name
Placebo
0
LY3471851
0
Interventional Trial Phase
Phase 2
0
Interventional Trial Purpose
Treatment
0
Intervention Type
Drug
0
Last Updated
November 18, 2023
0
Masked Party
Participant
0
Investigator
0
Masking Type
Double
0
Primary Completion Date
January 10, 2023
0
Trial Recruitment Size
291
0
Trial Sponsor
Nektar Therapeutics
0
Clinical Trial Start Date
August 19, 2020
0
Study Completion Date
February 16, 2023
0
Clinical Trial Study Type
Interventional
0
NCT Number
NCT04433585
0
Official Name
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of LY3471851 (NKTR-358) in Adults With Systemic Lupus Erythematosus
0
Official Website
clinicaltrials.gov/study...433585
0
Find more entities like A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE)
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Company
Home
Press & Media
Blog
Careers
WE'RE HIRING
Products
Knowledge Graph
Query Tool
Data Requests
Knowledge Storage
API
Pricing
Enterprise
ChatGPT Plugin
Legal
Terms of Service
Enterprise Terms of Service
Privacy Policy
Help
Help center
API Documentation
Contact Us
By using this site, you agree to our
Terms of Service
.
SUBSCRIBE